MAP2K7 and neoplasm: While KRASG12C inhibitors have only recently been approved for clinical use, MEK inhibitors, targeting the MAPK pathway downstream of KRAS, have been used for some time and can result in similar tumor cell–intrinsic immunomodulatory changes (45) and in some cases have shown to ameliorate antitumor immunity (46–49).